Neurogene (NGNE) Non-Current Deffered Revenue (2016 - 2018)
Neurogene's (NGNE) quarterly Non-Current Deffered Revenue came in at $313000.0 in Q4 2018, down 30.91% YoY from $453000.0 in Q4 2017, and down 6.01% on a QoQ basis from $333000.0 in Q3 2018.
Powered by 
Analysis
Neurogene (NGNE) Non-Current Deffered Revenue (2016 - 2018) Analysis & Trends
Neurogene (NGNE) has 3 years of Non-Current Deffered Revenue data on file, last reported at $313000.0 in Q4 2018.
- Quarterly Non-Current Deffered Revenue fell 30.91% year-over-year to $313000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $313000.0 (down 30.91% YoY) and the FY2018 annual result came in at $313000.0, down 30.91% from the prior year.
- Non-Current Deffered Revenue declined to $313000.0 in Q4 2018, from $333000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $518000.0 in Q1 2017 to a low of $25000.0 in Q1 2016.
- A 3-year average of $311666.7 and a median of $355000.0 in 2018 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2017 — Non-Current Deffered Revenue surged 1972.0% — and 2018, when it tumbled 30.91%.
- Tracing NGNE's Non-Current Deffered Revenue over 3 years: stood at $150000.0 in 2016, then surged by 202.0% to $453000.0 in 2017, then plunged by 30.91% to $313000.0 in 2018.
- The last three Non-Current Deffered Revenue figures came in at $313000.0 (Q4 2018), $333000.0 (Q3 2018), and $377000.0 (Q2 2018), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 313,000.00 |
| Sep 30, 2018 | 333,000.00 |
| Jun 30, 2018 | 377,000.00 |
| Mar 31, 2018 | 415,000.00 |
| Dec 31, 2017 | 453,000.00 |
| Sep 30, 2017 | 476,000.00 |
| Jun 30, 2017 | 508,000.00 |
| Mar 31, 2017 | 518,000.00 |
| Dec 31, 2016 | 150,000.00 |
| Sep 30, 2016 | 116,000.00 |
| Jun 30, 2016 | 56,000.00 |
| Mar 31, 2016 | 25,000.00 |